NASDAQ:SVRA
Savara Inc Stock News
$4.98
+0.130 (+2.68%)
At Close: Mar 28, 2024
3 stocks to turn $100 into $1,000 in 2024
06:40am, Thursday, 01'st Feb 2024
The previous year was prosperous for many investors, resulting in significant gains in the stock market. The outlook for 2024 seems promising, especially in the technology sector.
Savara to Present at Two Upcoming Healthcare Conferences
08:05am, Wednesday, 31'st Jan 2024
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will be participa
3 Penny Stocks to Provide 1,000% Returns Over the Next Decade
07:29pm, Wednesday, 27'th Sep 2023
While penny stocks promise substantial potential gains, the reality is that sub-$5 stocks are among the riskiest investments. Their low price often reflects underlying issues like weak business models
The 3 Best Penny Stocks to Buy Now: September 2023
09:12am, Tuesday, 12'th Sep 2023
A new month arrives and with it comes new investment opportunities. We will not always need such a large capital to make our investments, for these penny stocks present us with good opportunities that
Savara to Present at the H.C. Wainwright 25th Annual Global Investment Conference
04:05pm, Tuesday, 05'th Sep 2023
LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at t
Savara: A Speculative Play
11:50am, Sunday, 16'th Jul 2023
Today, we circle back on a small development firm called Savara for the first time in over two years. Its primary drug candidate is being developed for a rare affliction that has no approved therapies
Savara to Present at the Jefferies Healthcare Conference
08:05am, Friday, 02'nd Jun 2023
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will participate i
Why Shares of Savara Jumped on Tuesday
12:32pm, Tuesday, 16'th May 2023
Savara is a clinical-stage pharmaceutical company with no revenue. The company expects a top-line readout on molgramostim in the second quarter of 2024.
Savara to Present at the Oppenheimer 33rd Annual Healthcare Conference
04:05pm, Monday, 06'th Mar 2023
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that its management team will present at th
Why Shares of Savara Soared This Week
03:47pm, Friday, 27'th Jan 2023
The clinical-stage biopharmaceutical company focuses on therapies to treat rare respiratory diseases.
Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference
08:05am, Thursday, 01'st Sep 2022
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced that Matt Pauls, Chair and CEO, Savara will
Zacks.com featured highlights include Savara, The LGL Group, and Harte Hanks
10:19am, Monday, 11'th Jul 2022 Zacks Investment Research
Savara, The LGL Group, and Harte Hanks are part of zacks Screen of the Week article.
3 Top Breakout Stocks to Add to Your Portfolio Now
11:10am, Friday, 08'th Jul 2022 Zacks Investment Research
Savara (SVRA), LGL Group (LGL) and Harte Hanks (HHS) have been selected as the breakout stocks for today.
3 Top Breakout Stocks to Add to Your Portfolio Now
08:33am, Friday, 08'th Jul 2022
Savara (SVRA), LGL Group (LGL) and Harte Hanks (HHS) have been selected as the breakout stocks for today.
Has Assertio (ASRT) Outpaced Other Medical Stocks This Year?
01:40pm, Friday, 17'th Jun 2022 Zacks Investment Research
Here is how Assertio (ASRT) and Savara Inc. (SVRA) have performed compared to their sector so far this year.